Table 1.
Demographic and baseline characteristics (efficacy population)
| PA21 | Sevelamer-HCl (n=24) | ||||||
|---|---|---|---|---|---|---|---|
| 1.25 g/d (n=26) | 5.0 g/d (n=26) | 7.5 g/d (n=25) | 10.0 g/d (n=25) | 12.5 g/d (n=24) | All Participants (n=126) | ||
| Age (yr) | 60.1±12.3 | 59.7±13.8 | 61.9±13.7 | 60.8±13.2 | 59.3±12.3 | 60.4±12.9 | 61.6±11.2 |
| Male sex | 17 (65.4) | 19 (73.1) | 16 (64.0) | 15 (60.0) | 13 (54.2) | 80 (63.5) | 14 (58.3) |
| White race | 24 (92.3) | 26 (100.0) | 24 (96.0) | 22 (88.0) | 24 (100.0) | 120 (95.2) | 23 (95.8) |
| Concomitant diseasesa | |||||||
| Diabetes mellitus | 8 (30.8) | 7 (26.9) | 9 (36.0) | 7 (28.0) | 9 (37.5) | 40 (31.8) | 9 (37.5) |
| Hypertension | 18 (69.2) | 21 (80.8) | 20 (80.0) | 16 (64.0) | 20 (83.3) | 95 (75.4) | 16 (66.7) |
| Causes of CKDa | |||||||
| Glomerulopathy | 7 (26.9) | 4 (15.4) | 6 (24.0) | 8 (32.0) | 5 (20.8) | 30 (23.8) | 7 (29.2) |
| Vascular nephropathy | 7 (26.9) | 4 (15.4) | 5 (20.0) | 7 (28.0) | 3 (12.5) | 26 (20.6) | 3 (12.5) |
| Interstitial nephropathy | 2 (7.7) | 2 (7.7) | 4 (16.0) | 3 (12.0) | 4 (16.7) | 15 (11.9) | 3 (12.5) |
| Other, not specified | 9 (34.6) | 16 (61.5) | 9 (36.0) | 7 (28.0) | 12 (50.0) | 53 (42.1) | 11 (45.8) |
| Duration since first diagnosis of CKD (mo)b | 40.8 (17.5;68.8) | 47.3 (21.9;107.7) | 63.6 (23.7;114.0) | 48.9 (16.0;119.6) | 74.0 (30.2;131.9) | 54.2 (21.9;107.3) | 65.0 (28.8;126.1) |
| Serum creatinine (mg/dl) | 8.9 (8.4;10.9) | 10.2 (7.6;11.9) | 9.7 (8.5;11.3) | 9.7 (8.0;13.0) | 9.4 (7.8;11.3) | 9.5 (8.1;11.5) | 9.8 (8.4;11.1) |
Values are shown as mean ± SD for normally distributed parameters, n (%), or median (interquartile range) for non-normally distributed parameters.
a
Several causes per patient possible.
b
The difference between month and year of screening visit and month and year of the first diagnosis of CKD.